Resources for IV Fluid Shortages

ASPEN Resources

• Clinical Considerations in Conversion of Dextrose Injection USP to Glucose 50% Injection
  
• 2024 Parenteral Nutrition Product Shortage Recommendations: Intravenous Dextrose
  
• 2024 Parenteral Nutrition Product Shortage Recommendations: Sterile Water for Injection
  
• ASPEN PN Shortage Recommendations
• PN Indications: When is PN Appropriate?
• EN Indications: When is Enteral Nutrition Indicated?
• Appropriate Dosing for PN: ASPEN Recommendations
• Multi-Chamber Bag PN: Indications, Product Availability, and Patient Safety
• Submit your experiences, concerns, and/or resources to ASPEN.
  

External Resources

• New FDA Guidance: Temporary Policies for Compounding Certain Parenteral Drug Products
• ASPEN Response to FDA Temporary Guidance: ASPEN urges anyone involved in the preparation and administration of PN to follow previous USP <797> BUD recommendations of 30 hours at room temperature and 9 days refrigerated for all PN formulations.
• USP Operational considerations for sterile compounding during public health emergencies
  
• Hurricane Helene Clinical Resources – Baxter
• ISMP Imported Fluid Product Checklist
  
• NHIA Guidance Document for Addressing Product Shortages During Disruptions in Manufacturing
• ASHP Small- and Large-Volume Fluid Shortages – Suggestions for Management and Conservation
• ASHP Fluid Shortage Importation Risk Mitigation Strategies
  
• INS Guidance to Address IV Fluid Shortages
  
• ISMP Medication Error Reporting
• ORS: The Solutions to Optimize Hydration in Short Bowel Syndrome

Updates and Customer Letters

• Baxter – Hurricane Helene Updates
  
• December 13: Baxter Updated Allocation Letter
  
• December 3: Temporary Authorization of Import Products
• November 14: Temporary Importation Products
• November 11: Anticipated Allocation Changes for U.S. IV Products
• October 28: Extended Expiration Dates
• October 12: Protective Allocation for IV Sets
• October 9: Baxter Updated Allocation Letter
• October 1: Baxter Original Allocation Letter
• September 30: Baxter Original Communication Letter on North Cove, NC Facility Disruption of Site Operations
• FDA – Hurricane Helene Updates